Search Results 631-640 of 15966 for SC

  1. Publications - Jerry D. Brewer, M.D., M.S. - Mayo Clinic

    Lalla SC, Kumar AB, Lehman JS, Lohse CM, Brewer JD. Association of BRAF V600E Status of Incident Melanoma and Risk for a Second Primary Malignancy: A ...

  2. Publications - Ande M. Rumilla, M.D. - Mayo Clinic

    Graham RP, Dina MA, Howe SC, Butz ML, Willkomm KS, Murray DL, Snyder MR, Rumilla KM, Halling KC, Highsmith WE Jr. SERPINA1 Full-Gene Sequencing Identifies ...

  3. Multiple Myeloma Clinical Trials - Mayo Clinic Research

    The primary purpose of this study is to assess the efficacy (overall response rate) of subcutaneous (SC) via on body delivery system (SC-OBDS) isatuximab in ...

  4. Publications - Andrew C. Storm, M.D. - Mayo Clinic

    Epub 2023 May 16. View PubMed; Pawa S, Kwon RS, Fishman DS, Thosani NC, Shergill A, Grover SC, Al-Haddad M, Amateau SK, Buxbaum JL, Calderwood AH, Chalhoub ...

  5. Study to Evaluate the Safety and Effectiveness of BMS-986036 in Adults with Nonalcoholic Steatophepatitis (NASH) and Stage 3 Liver Fibrosis - Mayo Clinic

    Inability to tolerate SC medication;; Inability to tolerate venipuncture;; Women who are breastfeeding;. Prior and concomitant therapy: Participants who have ...

  6. Male Breast Cancer Clinical Trials - Mayo Clinic Research

    The purpose of this study is to assess the safety of PH FDC SC when administered at home by an HHNP. Patients will be assessed for safety by regular ...

  7. A Study to Evaluate Lumasiran in Children and Adults With Primary Hyperoxaluria Type 1 - Mayo Clinic

    History of intolerance to subcutaneous (SC) injection(s(. Is not willing to comply with the contraceptive requirements during the study period. Female ...

  8. Lupus Clinical Trials - Mayo Clinic Research

    The purpose of this trial is to evaluate the effectiveness, safety, and tolerability of subcutaneous (s.c.) ianalumab given every 4 weeks (q4w) or every 12 ...

  9. Biological Therapy For Cancer Clinical Trials - Mayo Clinic Research

    The purpose of this study is to assess the patient's preference for nivolumab subcutaneous (SC) or nivolumab + relatlimab fixed-dose combination (FDC) SC and ...

  10. Untitled

    Sc.B., Ecology and. Evolutionary Biology. Brown University. Providence, RI. Residency, Ophthalmology. University of New Mexico. School of Medicine. Albuquerque, ...